Michihisa Moriguchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michihisa Moriguchi has a total of 187 co-authors. Here are the top co-authors by number of shared publications:
- Atsushi Umemura
Department of Pharmacology, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan
13 shared publications - Yoshito Itoh
Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto 6028566, Japan
13 shared publications - Yuya Seko
Molecular Gastroenterology and Hepatology, Graduate School of Medical Science Kyoto Prefectural University of Medicine Kyoto Japan
13 shared publications - Kanji Yamaguchi
Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
10 shared publications - Seita Kataoka
Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto 602-8566, Japan
10 shared publications Yoshito Itoh
Molecular Gastroenterology and Hepatology, Graduate School of Medical Science Kyoto Prefectural University of Medicine Kyoto Japan
8 shared publications
Latest Publications
- Open Access
- 18 February 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (2) , e71655
Durable Disease Control With Atezolizumab Plus Bevacizumab but Limited Post‐Progression Outcomes: A Multicenter Real‐World Study in Advanced Hepatocellular Carcinoma
Introduction: Atezolizumab plus bevacizumab (Atez/Bev) has become the standard first‐line therapy for advanced hepatocellular carcinoma (HCC), but optimal second‐line strategies remain unclear. This multicenter retrospective study compared survival outcomes and tumor control among first‐line regimens and evaluated post‐progression efficacy. Methods: We retrospectively analyzed 1542 patients with advanced HCC who received sorafenib (SOR), lenvatinib (LEN), or Atez/Bev between 2009 and 2022. The main cohort ( n = 612) excluded patients who underwent concomitant or inter‐line locoregional therapy or entered clinical trials after first‐line treatment. Overall survival (OS), progression‐free survival (PFS), post‐progression survival (PPS), duration of disease control (DDC), and duration of response (DOR) were estimated by Kaplan–Meier analysis and compared by the log‐rank test. The impact of disease control and objective response on OS was assessed using time‐dependent Cox models. Results: Median OS was 15.4 months for SOR, 13.1 for LEN, and 20.6 for Atez/Bev ( p = 0.002); Median PFS was 3.5, 5.7, and 7.5 months, respectively ( p < 0.001); and median PPS was 10.8, 6.4, and 9.0 months, respectively ( p = 0.049). Atez/Bev achieved the longest DDC (8.5 months) and DOR (22.1 months). Disease control and objective response were associated with improved OS (HR: 0.51/0.42 for SOR, 0.54/0.62 for LEN, 0.34/0.35 for Atez/Bev). After progression, median second‐line PFS was 5.5 months for SOR, 2.5 for LEN, and 3.0 for Atez/Bev ( p = 0.001). Conclusion: Atez/Bev provided superior survival and durable tumor control; however, post‐progression outcomes remained unsatisfactory, underscoring the need for improved second‐line approaches after Atez/Bev failure.
- 18 February 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (2) , e71655
Open AccessDurable Disease Control With Atezolizumab Plus Bevacizumab but Limited Post‐Progression Outcomes: A Multicenter Real‐World Study in Advanced Hepatocellular Carcinoma
Introduction: Atezolizumab plus bevacizumab (Atez/Bev) has become the standard first‐line therapy for advanced hepatocellular carcinoma (HCC), but optimal second‐line strategies remain unclear. This multicenter retrospective study compared survival outcomes and tumor control among first‐line regimens and evaluated post‐progression efficacy. Methods: We retrospectively analyzed 1542 patients with advanced HCC who received sorafenib (SOR), lenvatinib (LEN), or Atez/Bev between 2009 and 2022. The main cohort ( n = 612) excluded patients who underwent concomitant or inter‐line locoregional therapy or entered clinical trials after first‐line treatment. Overall survival (OS), progression‐free survival (PFS), post‐progression survival (PPS), duration of disease control (DDC), and duration of response (DOR) were estimated by Kaplan–Meier analysis and compared by the log‐rank test. The impact of disease control and objective response on OS was assessed using time‐dependent Cox models. Results: Median OS was 15.4 months for SOR, 13.1 for LEN, and 20.6 for Atez/Bev ( p = 0.002); Median PFS was 3.5, 5.7, and 7.5 months, respectively ( p < 0.001); and median PPS was 10.8, 6.4, and 9.0 months, respectively ( p = 0.049). Atez/Bev achieved the longest DDC (8.5 months) and DOR (22.1 months). Disease control and objective response were associated with improved OS (HR: 0.51/0.42 for SOR, 0.54/0.62 for LEN, 0.34/0.35 for Atez/Bev). After progression, median second‐line PFS was 5.5 months for SOR, 2.5 for LEN, and 3.0 for Atez/Bev ( p = 0.001). Conclusion: Atez/Bev provided superior survival and durable tumor control; however, post‐progression outcomes remained unsatisfactory, underscoring the need for improved second‐line approaches after Atez/Bev failure.
- 27 November 2025
- Published by Wiley in Hepatology Research
- Vol. 56 (4) , 411-419
Impact of PNPLA3 Genotype on Hepatic Steatosis Response to Pemafibrate in MASLD With Dyslipidemia
AIM: Pemafibrate, a selective peroxisome proliferator‐activated receptor‐α modulator (SPPARMα), improves liver enzymes in metabolic dysfunction–associated steatotic liver disease (MASLD). Whether treatment response is influenced by PNPLA3 genotype remains unclear. Methods: We retrospectively analyzed 93 Japanese patients with MASLD and dyslipidemia treated with pemafibrate for 48 weeks. Changes in controlled attenuation parameter (CAP), liver stiffness measurement (LSM), and FibroScan‐AST (FAST) score were compared according to PNPLA3 genotype. Results: Overall, ALT, AST, GGT, and lipid parameters decreased significantly, and FAST improved, whereas CAP showed no overall change. Stratified analysis revealed CAP decreased in PNPLA3 CC and CG but not in GG, with greater reduction in CC compared to CG or GG. Among patients with weight loss, the reduction in CAP did not differ significantly between genotypes. LSM changes were not genotype dependent. Conclusions: Pemafibrate reduced hepatic steatosis preferentially in PNPLA3 CC carriers, whereas PNPLA3 G‐allele carriers showed attenuated CAP improvement without weight loss. PNPLA3 polymorphism may influence steatosis‐lowering efficacy of pemafibrate, underscoring the need for genotype‐informed therapeutic strategies.
- 27 November 2025
- Published by Wiley in Hepatology Research
- Vol. 56 (4) , 411-419
Impact of PNPLA3 Genotype on Hepatic Steatosis Response to Pemafibrate in MASLD With Dyslipidemia
AIM: Pemafibrate, a selective peroxisome proliferator‐activated receptor‐α modulator (SPPARMα), improves liver enzymes in metabolic dysfunction–associated steatotic liver disease (MASLD). Whether treatment response is influenced by PNPLA3 genotype remains unclear. Methods: We retrospectively analyzed 93 Japanese patients with MASLD and dyslipidemia treated with pemafibrate for 48 weeks. Changes in controlled attenuation parameter (CAP), liver stiffness measurement (LSM), and FibroScan‐AST (FAST) score were compared according to PNPLA3 genotype. Results: Overall, ALT, AST, GGT, and lipid parameters decreased significantly, and FAST improved, whereas CAP showed no overall change. Stratified analysis revealed CAP decreased in PNPLA3 CC and CG but not in GG, with greater reduction in CC compared to CG or GG. Among patients with weight loss, the reduction in CAP did not differ significantly between genotypes. LSM changes were not genotype dependent. Conclusions: Pemafibrate reduced hepatic steatosis preferentially in PNPLA3 CC carriers, whereas PNPLA3 G‐allele carriers showed attenuated CAP improvement without weight loss. PNPLA3 polymorphism may influence steatosis‐lowering efficacy of pemafibrate, underscoring the need for genotype‐informed therapeutic strategies.
- Open Access
- 3 November 2025
- Published by Wiley in Liver International
- Vol. 45 (12) , e70379
Atezolizumab Plus Bevacizumab for TACE ‐Unsuitable Intermediate‐Stage HCC Beyond Up‐To‐7 Criteria: Final Analysis of REPLACEMENT
Background and Aims: The phase II REPLACEMENT study showed promising clinical benefit from atezolizumab plus bevacizumab in transcatheter arterial chemoembolization (TACE)–naïve patients with intermediate‐stage hepatocellular carcinoma (HCC) beyond up‐to‐7 criteria, meeting its primary endpoint of progression‐free survival (PFS). Here, we report the final overall survival (OS) analysis. Methods: Enrolled patients were naïve to TACE with unresectable intermediate‐stage HCC beyond up‐to‐7 criteria, had Child‐Pugh A, Eastern Cooperative Oncology Group performance status 0/1 and received no previous systemic therapy. Atezolizumab 1200 mg and bevacizumab 15 mg/kg were administered every 3 weeks. The primary endpoint was the 6‐month PFS rate by modified Response Evaluation Criteria in Solid Tumours for HCC (mRECIST); secondary endpoints included OS, PFS by RECIST version 1.1, objective response rate (ORR) and safety. Results: Overall, 74 patients were enrolled between December 2020 and September 2021. At the clinical cut‐off date (March 31, 2024), median follow‐up was 33.6 months. Median PFS by mRECIST was 9.1 months (95% CI 7.1–10.2). Median OS was 33.8 months (95% CI 22.6–not estimable). ORR was 40.5% (95% CI 29.3–52.6), with 12.2% of patients having a complete response. Overall, 82.4% of patients received subsequent therapy. All‐cause adverse events (AEs) were observed in 98.6% of patients, most commonly hypertension (71.6%) and proteinuria (54.1%). Grade 3/4 AEs occurred in 43.2% of patients; no Grade 5 AEs were reported. Conclusions: These results show that atezolizumab plus bevacizumab can be an alternative treatment option for patients with intermediate‐stage HCC beyond up‐to‐7 criteria who are deemed unsuitable for TACE. Trial Registration: jRCTs071200051
- 3 November 2025
- Published by Wiley in Liver International
- Vol. 45 (12) , e70379
Open AccessAtezolizumab Plus Bevacizumab for TACE ‐Unsuitable Intermediate‐Stage HCC Beyond Up‐To‐7 Criteria: Final Analysis of REPLACEMENT
Background and Aims: The phase II REPLACEMENT study showed promising clinical benefit from atezolizumab plus bevacizumab in transcatheter arterial chemoembolization (TACE)–naïve patients with intermediate‐stage hepatocellular carcinoma (HCC) beyond up‐to‐7 criteria, meeting its primary endpoint of progression‐free survival (PFS). Here, we report the final overall survival (OS) analysis. Methods: Enrolled patients were naïve to TACE with unresectable intermediate‐stage HCC beyond up‐to‐7 criteria, had Child‐Pugh A, Eastern Cooperative Oncology Group performance status 0/1 and received no previous systemic therapy. Atezolizumab 1200 mg and bevacizumab 15 mg/kg were administered every 3 weeks. The primary endpoint was the 6‐month PFS rate by modified Response Evaluation Criteria in Solid Tumours for HCC (mRECIST); secondary endpoints included OS, PFS by RECIST version 1.1, objective response rate (ORR) and safety. Results: Overall, 74 patients were enrolled between December 2020 and September 2021. At the clinical cut‐off date (March 31, 2024), median follow‐up was 33.6 months. Median PFS by mRECIST was 9.1 months (95% CI 7.1–10.2). Median OS was 33.8 months (95% CI 22.6–not estimable). ORR was 40.5% (95% CI 29.3–52.6), with 12.2% of patients having a complete response. Overall, 82.4% of patients received subsequent therapy. All‐cause adverse events (AEs) were observed in 98.6% of patients, most commonly hypertension (71.6%) and proteinuria (54.1%). Grade 3/4 AEs occurred in 43.2% of patients; no Grade 5 AEs were reported. Conclusions: These results show that atezolizumab plus bevacizumab can be an alternative treatment option for patients with intermediate‐stage HCC beyond up‐to‐7 criteria who are deemed unsuitable for TACE. Trial Registration: jRCTs071200051
- Open Access
- 6 October 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (1) , 1233-1243
Prognostic impact and predictive model for early non-curative recurrence after liver resection for hepatocellular carcinoma: a retrospective cohort study
Background: The prognostic impact of early non-curative recurrence after liver resection for hepatocellular carcinoma (HCC) and its predictive factors remain unknown. We aimed to identify independent predictive factors for early non-curative recurrence, develop a predictive model, and evaluate its clinical utility. Materials and Methods: We retrospectively analyzed 624 patients who underwent curative HCC resection between 2002 and 2020. Patients were randomly assigned to training ( n = 416) and validation ( n = 208) sets. Early recurrence was defined as recurrence within 2 years after surgery. Non-curative recurrence was defined as recurrence corresponding to the intermediate or advanced stage of the Barcelona Clinic Liver Cancer staging system based on tumor factors. A nomogram was constructed based on independent predictive factors identified via multivariate analysis. Model performance was assessed by the area under the receiver operating characteristic curve (AUC), calibration plots, and decision curve analysis. Results: Early non-curative recurrence was an independent prognostic factor for overall survival (OS) after surgery and OS after recurrence (hazard ratio = 5.387 and 2.806, P P P <0.001). Five factors were independently associated with early non-curative recurrence: alpha-fetoprotein, tumor size, number of tumors, portal invasion, and serosal invasion. The predictive model demonstrated high calibration performance in the training (AUC = 0.825) and validation (AUC = 0.792) sets. Decision curve analysis confirmed the clinical utility of the predictive model. Conclusion: We developed and validated a novel predictive model for early non-curative recurrence, which is significantly associated with poor prognosis after curative liver resection for HCC. Its application may enhance individualized postoperative surveillance and treatment strategies, potentially improving long-term outcomes.
- 6 October 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (1) , 1233-1243
Open AccessPrognostic impact and predictive model for early non-curative recurrence after liver resection for hepatocellular carcinoma: a retrospective cohort study
Background: The prognostic impact of early non-curative recurrence after liver resection for hepatocellular carcinoma (HCC) and its predictive factors remain unknown. We aimed to identify independent predictive factors for early non-curative recurrence, develop a predictive model, and evaluate its clinical utility. Materials and Methods: We retrospectively analyzed 624 patients who underwent curative HCC resection between 2002 and 2020. Patients were randomly assigned to training ( n = 416) and validation ( n = 208) sets. Early recurrence was defined as recurrence within 2 years after surgery. Non-curative recurrence was defined as recurrence corresponding to the intermediate or advanced stage of the Barcelona Clinic Liver Cancer staging system based on tumor factors. A nomogram was constructed based on independent predictive factors identified via multivariate analysis. Model performance was assessed by the area under the receiver operating characteristic curve (AUC), calibration plots, and decision curve analysis. Results: Early non-curative recurrence was an independent prognostic factor for overall survival (OS) after surgery and OS after recurrence (hazard ratio = 5.387 and 2.806, P P P <0.001). Five factors were independently associated with early non-curative recurrence: alpha-fetoprotein, tumor size, number of tumors, portal invasion, and serosal invasion. The predictive model demonstrated high calibration performance in the training (AUC = 0.825) and validation (AUC = 0.792) sets. Decision curve analysis confirmed the clinical utility of the predictive model. Conclusion: We developed and validated a novel predictive model for early non-curative recurrence, which is significantly associated with poor prognosis after curative liver resection for HCC. Its application may enhance individualized postoperative surveillance and treatment strategies, potentially improving long-term outcomes.
- Open Access
Evolution of Systemic Treatment for Hepatocellular Carcinoma: Changing Treatment Strategies and Concepts
Systemic therapy for hepatocellular carcinoma (HCC) has undergone substantial advancements. With the advent of atezolizumab plus bevacizumab (ATZ/BEV) combination therapy, followed by durvalumab plus tremelimumab, the era of immunotherapy for HCC has commenced. The emergence of systemic treatment with high response rates has led to improvements in overall survival while enabling conversion to radical surgical resection in some patients with HCC. In patients with intermediate-stage HCC, new treatment strategies combining systemic treatment and transcatheter arterial chemoembolization (TACE) are under development in clinical trials. Moreover, the addition of local therapies, such as TACE, to systemic treatment according to the treatment effect could achieve a certain percentage of complete response. In the IMbrave050 trial, the efficacy of ATZ/BEV combination therapy was validated in patients predicted to have a high risk of recurrence, especially in those who had undergone radical surgery or radiofrequency ablation for HCC. Therefore, systemic treatment for HCC is entering a new phase for all disease stages. The objective of this review is to organize the current position of systemic therapy for each HCC stage and discuss the development of new treatment methods and strategies, with a focus on regimens incorporating immune checkpoint inhibitors, along with future prospects.
Open AccessEvolution of Systemic Treatment for Hepatocellular Carcinoma: Changing Treatment Strategies and Concepts
Systemic therapy for hepatocellular carcinoma (HCC) has undergone substantial advancements. With the advent of atezolizumab plus bevacizumab (ATZ/BEV) combination therapy, followed by durvalumab plus tremelimumab, the era of immunotherapy for HCC has commenced. The emergence of systemic treatment with high response rates has led to improvements in overall survival while enabling conversion to radical surgical resection in some patients with HCC. In patients with intermediate-stage HCC, new treatment strategies combining systemic treatment and transcatheter arterial chemoembolization (TACE) are under development in clinical trials. Moreover, the addition of local therapies, such as TACE, to systemic treatment according to the treatment effect could achieve a certain percentage of complete response. In the IMbrave050 trial, the efficacy of ATZ/BEV combination therapy was validated in patients predicted to have a high risk of recurrence, especially in those who had undergone radical surgery or radiofrequency ablation for HCC. Therefore, systemic treatment for HCC is entering a new phase for all disease stages. The objective of this review is to organize the current position of systemic therapy for each HCC stage and discuss the development of new treatment methods and strategies, with a focus on regimens incorporating immune checkpoint inhibitors, along with future prospects.
- 4 June 2024
- Published by Wiley in Liver International
- Vol. 44 (8) , 1751-1761
Safety/efficacy of atezolizumab + bevacizumab during anti‐platelet/anticoagulation therapy in unresectable hepatocellular carcinoma
Background and Aims: This study aimed to determine the safety and efficacy of atezolizumab + bevacizumab therapy in hepatocellular carcinoma patients receiving anti‐platelet agents or anticoagulants. Methods: Patients were divided into those using (IM out) and those not using (IM in) anti‐platelet agents or anticoagulants, who violated the exclusion criteria of the IMbrave150 trial, and were retrospectively examined. Results: The study included 185 patients (IM in: 157; IM out: 28). For first‐line treatment, progression‐free survival was 184 days for IM in and 266 days for IM out ( p = .136). Overall survival was 603 days for IM in and not reached for IM out ( p = .265), with no significant between‐group difference. Similarly, there were no significant between‐group differences in progression‐free survival or overall survival for later‐line treatment. Haemorrhagic adverse events of ≥grade 3 were observed in 11 IM in patients and 3 IM out patients. No significant factors associated with haemorrhagic adverse events of ≥grade 3 were identified in the multivariate analysis including IM out classification, whose p value was .547. Regarding thrombotic/embolic adverse events in the IM out group, one case of exacerbation of portal vein thrombosis was observed. No deaths were directly attributable to bleeding events or exacerbations of thrombosis. Conclusion: Atezolizumab + bevacizumab therapy shows similar safety and efficacy in patients receiving and those not receiving anti‐platelet agents or anticoagulants; therefore, it can be considered for patients with hepatocellular carcinoma receiving anti‐platelet agents or anticoagulants.
- 4 June 2024
- Published by Wiley in Liver International
- Vol. 44 (8) , 1751-1761
Safety/efficacy of atezolizumab + bevacizumab during anti‐platelet/anticoagulation therapy in unresectable hepatocellular carcinoma
Background and Aims: This study aimed to determine the safety and efficacy of atezolizumab + bevacizumab therapy in hepatocellular carcinoma patients receiving anti‐platelet agents or anticoagulants. Methods: Patients were divided into those using (IM out) and those not using (IM in) anti‐platelet agents or anticoagulants, who violated the exclusion criteria of the IMbrave150 trial, and were retrospectively examined. Results: The study included 185 patients (IM in: 157; IM out: 28). For first‐line treatment, progression‐free survival was 184 days for IM in and 266 days for IM out ( p = .136). Overall survival was 603 days for IM in and not reached for IM out ( p = .265), with no significant between‐group difference. Similarly, there were no significant between‐group differences in progression‐free survival or overall survival for later‐line treatment. Haemorrhagic adverse events of ≥grade 3 were observed in 11 IM in patients and 3 IM out patients. No significant factors associated with haemorrhagic adverse events of ≥grade 3 were identified in the multivariate analysis including IM out classification, whose p value was .547. Regarding thrombotic/embolic adverse events in the IM out group, one case of exacerbation of portal vein thrombosis was observed. No deaths were directly attributable to bleeding events or exacerbations of thrombosis. Conclusion: Atezolizumab + bevacizumab therapy shows similar safety and efficacy in patients receiving and those not receiving anti‐platelet agents or anticoagulants; therefore, it can be considered for patients with hepatocellular carcinoma receiving anti‐platelet agents or anticoagulants.
- 5 October 2023
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (23) , 4760-4769
A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
Purpose: This study aimed to investigate the safety and efficacy of lenvatinib in real-world settings, including patients excluded from the REFLECT trial, a phase III trial that compared lenvatinib with sorafenib. Patients and Methods: This multicenter, nonrandomized, open-label prospective study was conducted at 10 medical facilities in Japan (jRCTs031190017). Eligible patients had advanced hepatocellular carcinoma (HCC) and were suitable for lenvatinib therapy. The study included patients with high tumor burden (with >50% intrahepatic tumor volume, main portal vein invasion, or bile duct invasion), Child-Pugh B status, and receiving lenvatinib as second-line therapy following atezolizumab plus bevacizumab. Results: From December 2019 to September 2021, 59 patients were analyzed (47 and 12 patients with Child-Pugh A and B, respectively). In patients with Child-Pugh A, the frequency of aspartate aminotransferase elevation was high (72.7%) in the high-burden group. No other significant ad verse events (AE) were observed even in second-line treatment. However, patients with Child-Pugh B had high incidence of grade ≥3 AE (100.0%) and high discontinuation rates caused by AE (33.3%) compared with patients with Child-Pugh A (80.9% and 17.0%, respectively). Median progression-free survival was 6.4 and 2.5 months and median overall survival was 19.7 and 4.1 months in Child-Pugh A and B, respectively. Lenvatinib plasma concentration was higher in patients with Child-Pugh B on days 8 and 15 and correlated with dose modifications and lower relative dose intensity. Conclusions: Lenvatinib is safe and effective for advanced HCC in patients with Child-Pugh A, even with high tumor burden. However, it carries a higher risk of AE and may not provide adequate efficacy for patients with Child-Pugh B status.
- 5 October 2023
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (23) , 4760-4769
A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
Purpose: This study aimed to investigate the safety and efficacy of lenvatinib in real-world settings, including patients excluded from the REFLECT trial, a phase III trial that compared lenvatinib with sorafenib. Patients and Methods: This multicenter, nonrandomized, open-label prospective study was conducted at 10 medical facilities in Japan (jRCTs031190017). Eligible patients had advanced hepatocellular carcinoma (HCC) and were suitable for lenvatinib therapy. The study included patients with high tumor burden (with >50% intrahepatic tumor volume, main portal vein invasion, or bile duct invasion), Child-Pugh B status, and receiving lenvatinib as second-line therapy following atezolizumab plus bevacizumab. Results: From December 2019 to September 2021, 59 patients were analyzed (47 and 12 patients with Child-Pugh A and B, respectively). In patients with Child-Pugh A, the frequency of aspartate aminotransferase elevation was high (72.7%) in the high-burden group. No other significant ad verse events (AE) were observed even in second-line treatment. However, patients with Child-Pugh B had high incidence of grade ≥3 AE (100.0%) and high discontinuation rates caused by AE (33.3%) compared with patients with Child-Pugh A (80.9% and 17.0%, respectively). Median progression-free survival was 6.4 and 2.5 months and median overall survival was 19.7 and 4.1 months in Child-Pugh A and B, respectively. Lenvatinib plasma concentration was higher in patients with Child-Pugh B on days 8 and 15 and correlated with dose modifications and lower relative dose intensity. Conclusions: Lenvatinib is safe and effective for advanced HCC in patients with Child-Pugh A, even with high tumor burden. However, it carries a higher risk of AE and may not provide adequate efficacy for patients with Child-Pugh B status.
- Open Access
- 14 April 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (4) , 901
Potential Therapeutic Targets and Promising Agents for Combating NAFLD
Nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH), is a growing cause of liver cirrhosis and liver cancer worldwide because of the global increases in obesity, dyslipidemia, hypertension, and type 2 diabetes mellitus. Contrary to the advancements in therapies for viral hepatitis, effective treatments remain unestablished for patients with NAFLD. NAFLD, including NASH, is characterized by steatosis, inflammation, hepatic necrosis, and fibrosis. Despite our understanding of its pathophysiology, there are currently no effective treatments for NAFLD. In this review, we provide an update on the known pathophysiological mechanisms involved in the development of NAFLD and the role of hepatic stellate cells, and summarize the potential therapeutic agents, including natural products, for NAFLD.
- 14 April 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (4) , 901
Open AccessPotential Therapeutic Targets and Promising Agents for Combating NAFLD
Nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH), is a growing cause of liver cirrhosis and liver cancer worldwide because of the global increases in obesity, dyslipidemia, hypertension, and type 2 diabetes mellitus. Contrary to the advancements in therapies for viral hepatitis, effective treatments remain unestablished for patients with NAFLD. NAFLD, including NASH, is characterized by steatosis, inflammation, hepatic necrosis, and fibrosis. Despite our understanding of its pathophysiology, there are currently no effective treatments for NAFLD. In this review, we provide an update on the known pathophysiological mechanisms involved in the development of NAFLD and the role of hepatic stellate cells, and summarize the potential therapeutic agents, including natural products, for NAFLD.
- 15 January 2022
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 57 (2) , 90-98
Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents
Background The aim of this multicenter retrospective study was to evaluate the impact of the eradication of hepatitis C virus (HCV) on the clinical outcomes of patients with hepatocellular carcinoma (HCC) treated with molecular-targeted agents (MTAs). Methods Among 877 patients who received any MTA as first-line systemic therapy for HCC between June 2009 and March 2019, 569 patients with HCV-related HCC were enrolled in this retrospective study. Of these, 109 patients achieved sustained virological response (SVR) before starting MTA. After propensity score matching, the clinical outcomes of 109 patients in the SVR group and 109 patients in the non-SVR group were compared. Results The median time to progression in the SVR group (7.8 months) was similar to that in the non-SVR group (5.6 months) (p = 0.212). The median time to treatment failure in the SVR group (5.3 months) was longer than that in the non-SVR group (2.8 months) (p = 0.059), and post-progression survival and overall survival in the SVR group were significantly longer than those in the non-SVR group (12.0 months vs 7.2 months; p = 0.039, and 18.1 months vs 11.3 months; p = 0.019). At the end of first-line MTA therapy, the albumin–bilirubin (ALBI) score in the SVR group ( – 2.25) was significantly lower than that in the non-SVR group ( – 2.10) (p = 0.008). Conclusions The eradication of HCV before MTA therapy maintained liver function and led to a prolonged treatment period and improved overall survival of HCV-related HCC patients. We should not overlook the benefits of HCV eradication in HCC patients.
- 15 January 2022
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 57 (2) , 90-98
Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents
Background The aim of this multicenter retrospective study was to evaluate the impact of the eradication of hepatitis C virus (HCV) on the clinical outcomes of patients with hepatocellular carcinoma (HCC) treated with molecular-targeted agents (MTAs). Methods Among 877 patients who received any MTA as first-line systemic therapy for HCC between June 2009 and March 2019, 569 patients with HCV-related HCC were enrolled in this retrospective study. Of these, 109 patients achieved sustained virological response (SVR) before starting MTA. After propensity score matching, the clinical outcomes of 109 patients in the SVR group and 109 patients in the non-SVR group were compared. Results The median time to progression in the SVR group (7.8 months) was similar to that in the non-SVR group (5.6 months) (p = 0.212). The median time to treatment failure in the SVR group (5.3 months) was longer than that in the non-SVR group (2.8 months) (p = 0.059), and post-progression survival and overall survival in the SVR group were significantly longer than those in the non-SVR group (12.0 months vs 7.2 months; p = 0.039, and 18.1 months vs 11.3 months; p = 0.019). At the end of first-line MTA therapy, the albumin–bilirubin (ALBI) score in the SVR group ( – 2.25) was significantly lower than that in the non-SVR group ( – 2.10) (p = 0.008). Conclusions The eradication of HCV before MTA therapy maintained liver function and led to a prolonged treatment period and improved overall survival of HCV-related HCC patients. We should not overlook the benefits of HCV eradication in HCC patients.
- Open Access
- 12 December 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (24) , 13354
Honokiol Acts as a Potent Anti-Fibrotic Agent in the Liver through Inhibition of TGF-β1/SMAD Signaling and Autophagy in Hepatic Stellate Cells
Chronic liver injury may result in hepatic fibrosis, which can progress to cirrhosis and eventually liver failure. There are no drugs that are specifically approved for treating hepatic fibrosis. The natural product honokiol (HNK), a bioactive compound extracted from Magnolia grandiflora, represents a potential tool in the management of hepatic fibrosis. Though HNK has been reported to exhibit suppressive effects in a rat fibrosis model, the mechanisms accounting for this suppression remain unclear. In the present study, the anti-fibrotic effects of HNK on the liver were evaluated in vivo and in vitro. In vivo studies utilized a murine liver fibrosis model, in which fibrosis is induced by treatment with carbon tetrachloride (CCl4). For in vitro studies, LX-2 human hepatic stellate cells (HSCs) were treated with HNK, and expression of markers of fibrosis, cell viability, the transforming growth factor-β (TGF-β1)/SMAD signaling pathway, and autophagy were analyzed. HNK was well tolerated and significantly attenuated CCl4-induced liver fibrosis in vivo. Moreover, HNK decreased HSC activation and collagen expression by downregulating the TGF-β1/SMAD signaling pathway and autophagy. These results suggest that HNK is a new potential candidate for the treatment of hepatic fibrosis through suppressing both TGF-β1/SMAD signaling and autophagy in HSCs.
- 12 December 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (24) , 13354
Open AccessHonokiol Acts as a Potent Anti-Fibrotic Agent in the Liver through Inhibition of TGF-β1/SMAD Signaling and Autophagy in Hepatic Stellate Cells
Chronic liver injury may result in hepatic fibrosis, which can progress to cirrhosis and eventually liver failure. There are no drugs that are specifically approved for treating hepatic fibrosis. The natural product honokiol (HNK), a bioactive compound extracted from Magnolia grandiflora, represents a potential tool in the management of hepatic fibrosis. Though HNK has been reported to exhibit suppressive effects in a rat fibrosis model, the mechanisms accounting for this suppression remain unclear. In the present study, the anti-fibrotic effects of HNK on the liver were evaluated in vivo and in vitro. In vivo studies utilized a murine liver fibrosis model, in which fibrosis is induced by treatment with carbon tetrachloride (CCl4). For in vitro studies, LX-2 human hepatic stellate cells (HSCs) were treated with HNK, and expression of markers of fibrosis, cell viability, the transforming growth factor-β (TGF-β1)/SMAD signaling pathway, and autophagy were analyzed. HNK was well tolerated and significantly attenuated CCl4-induced liver fibrosis in vivo. Moreover, HNK decreased HSC activation and collagen expression by downregulating the TGF-β1/SMAD signaling pathway and autophagy. These results suggest that HNK is a new potential candidate for the treatment of hepatic fibrosis through suppressing both TGF-β1/SMAD signaling and autophagy in HSCs.